Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dental membrane safety under review: will it hold up in Real-World use?

NCT ID NCT07153185

Knowledge-focused Sponsor: Nobel Biocare Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks back at the records of 200 people who had a biodegradable dental membrane called Creos xenoprotect placed during bone-grafting procedures. The goal is to see how often major complications (like infection or membrane exposure) happen within 6 months. Researchers will also check if the bone graft was successful. Since this is a retrospective study, no new treatments or visits are required.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
biodegradable dental barrier membrane (Creos xenoprotect)
What this could lead to
If successful, this study could confirm that the membrane is safe and effective for common dental bone-regeneration procedures.
What could go wrong
This is a retrospective study that only reviews past records, so it cannot prove cause and effect. Results may be limited by incomplete data or selection bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants (aged ≥ 18y) that underwent guided bone regeneration combined with the use of creos xenoprotect according to one of the four indications are included in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant was treated before December 2023 (creos xenoprotect placement) * Participant signed informed consent form and data protection consent form1 * Participant was at least 18 years old at the time of treatment * Participant received guided bone regeneration combined with the use of creos xenoprotect according to one of the four indications * Participant was treated according to instructions for use (IFU) * Participant should have follow-up time of \>9 months after placement of the investigational device Exclusion Criteria: * In Group 3: Sinus floor augmentation (lateral approach): usage of creos xenoprotect to replace a ruptured Schneiderian Membrane

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone grafting are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone grafting Bone regeneration Dental implants

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.